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CObjective: To describe rank reversal as a source of inconsistent interpre-
tation intrinsic to indirect comparison (Bucher HC, Guyatt GH, Griffith LE,
Walter SD. The results of direct and indirect treatment comparisons in
meta-analysis of randomized controlled trials. J Clin Epi 1997;50:683–91) of
treatments and to propose best practice. Methods: We prove our main
points with intuition, examples, graphs, and mathematical proofs. We
also provide software and discuss implications for research and policy.
Results: When comparing treatments by indirect means and sorting
them by effect size, three common measures of comparison (risk ratio, O
b
5 Wa
ty fo
http://dx.doi.org/10.1016/j.jval.2012.06.001isk difference, and odds ratio) may lead to vastly different rankings.
onclusions: The choice of risk measure matters whenmaking indirect
omparisons of treatments. The choice should depend primarily on the
tudy design and the conceptual framework for that study.
eywords: indirect comparisons, risk, risk difference, risk ratio, odds
atio.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
When a direct comparison of two or more treatments within the
same study is not possible, researchers must instead make indirect
comparisons of those treatments across different trials. Bucher et al.
[1] first showed how to conduct an indirect comparisonmeta-analy-
sis. Under the assumption that the relative efficacy of the treatments
is consistent for patients in the different trials [2,3], Bucher et al. [1]
showed that the log odds of the adjusted indirect comparison of two
treatments (each comparedwith a placebo or common control treat-
ment) is a simple function—thedifference in the logodds ratio (OR)of
each treatment compared with its control. Their basic method has
proved quite influential. While others have expanded upon it [3–5],
he basic model has been used in numerous meta-analyses.
Although Bucher et al. present their model by using ORs, they
lso assert that the “method could be equally applied to estimates
f relative risk” [1, p. 684]. Song et al. [2, p. 489] state that Bucher’s
ethod of adjusted indirect comparison “may also be used when
he relative efficacy ismeasured by risk ratio or by risk difference.”
ndeed, there are a few studies that have modified the formulas
ppropriately and used either the risk ratio (RR) or the risk differ-
nce (RD) instead of the more common OR (e.g., [6]).
The central point of this article is that when indirectly compar-
ng two or more treatments, the choice of how to express results
ay directly affect the conclusion. In other words, when sorting
reatments by effect size (whichwe refer to as ranking), the choice
etween RR, RD, and OR matters. We describe these three mea-
ures and showwhen indirect comparisons using any of the mea-
ures will be different from the others. We illustrate our results
* Address correspondence to: Edward C. Norton, M3108 SPH II, 141
E-mail: ecnorton@umich.edu.
1098-3015 – see front matter Copyright © 2012, International Socie
Published by Elsevier Inc.with intuition, examples, graphs, and mathematical proofs. We
are unaware of previous description of this phenomenon, which
we call rank reversal.
We explain ourmain points in the context of an indirect compar-
isonmeta-analysis, whereby two treatments (let’s call themAandB)
are each compared with a control (called C) in separate studies. The
goal is to use the information in these two separate studies to indi-
rectly compare treatments A and B, and thereby rank their effective-
ness. For example, compared with a placebo, is the desirable out-
come more likely when a patient takes drug A rather than drug B?
Theanswer to this question is important for bothpractice andpolicy.
As we explain, answering this question is not always straightfor-
ward.Whencomparedwith their respective placebos, drugAmaybe
preferred to drug B when measured by an RR, but drug B may be
preferred to drug A whenmeasured by an OR, even though both OR
and RR are measures of relative effectiveness.
We prove that rankings are not always consistent across these
risk measures, describe under what circumstances the rankings
are the same or different, explain how uncertainty affects the
main results, introduce software that can help identify problems,
discuss implications, and recommend best practice for research
and policy.When the study design is such that the results could be
expressed in terms of either RRs or ORs, the burden is on the
researcher to specify a conceptual framework tomake that choice.
Methods
Consider pairs of probabilities R0, R1, with R0 referring to the
aseline (control) risk and R1 to the risk if treated. These risks
shington Heights, University of Michigan, Ann Arbor, MI 48109.
r Pharmacoeconomics and Outcomes Research (ISPOR).
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1138 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 1 3 7 – 1 1 4 0are defined as probabilities of an event during a specified period
of time [7], and so are bounded by 0 and 1. For any pair of
probabilities R0, R1 we can define the RR, RD, and OR with R0 as
he reference.
R
R1
R0
(1)
RDR1R0 (2)
R
R1
1R1
R0
1R0
(3)
We state two proofs and direct the reader to the Appendix in Sup-
lemental Materials found at http://dx.doi.org/10.1016/j.jval.
012.06.001 for the details of those proofs. First, within a single
tudy, in which baseline risk is the same, treatment alternatives
ill have the same ranking regardless of the riskmeasure used. In
ther words, all three risk measures are strictly monotonic in
hanges in risk to the treatment group R1. Second, if both R0 and R1
are allowed to change, then there can be rank reversal. That is, two
treatment optionsA andB and their respective control treatments,
represented by the pairs of points R0A, R1A and R0B, R1B, may be
ranked differently by the RR, RD, and OR. The total derivative of
each measure (with respect to both R0 and R1) can have different
signs, indicating rank reversal. For details, see the Appendix in
upplemental Materials found at http://dx.doi.org/10.1016/j.
val.2012.06.001.
Graphs
It is easy to show rank reversal with graphs (see [8] for similar
graphs). Each pair of probabilities can be plotted on a unit square
graph. If treatment and baseline risks are the same, that is, R1 
0, then the point falls along the 45-degree line. If the treatment
isk is higher than the baseline risk, then the point lies to the
orthwest of the 45-degree line.
For any point R0, R1 on the graph, isoquants show all other
pointswith the same value of the RR, RD, or OR—see Figure 1 for an
examplewith R0, R1 0.4,0.6. Isoquants are a set of points (lines)
hat all have the same value of a quantity, such as the RR, RD, or
R. By definition, all three isoquants in this example must pass
hrough the point (0.4, 0.6). The RR isoquant is a ray from the origin
ith a slope of 1.5  0.6/0.4. The RD isoquant is parallel to the
5-degree line, with the intercept on the y-axis equal to 0.2 
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Isoquants for RR, RD, and OR through (.4,.6)
Fig 1 – Isoquants for the point (.4, .6). OR, odds ratio; RD,
risk difference; RR, risk ratio..60.4. The OR isoquant is an arc connecting the origin to the
oint (1, 1) such that the OR along the arc is always 2.25  0.6⁄
1  0.6 ⁄ 0.4 ⁄ 1  0.4.
The intuition of the first proof is shown graphically by mov-
ng due north of (0.4, 0.6) in Figure 1. All those northerly points
ie on isoquants representing RR values greater than 1.5, RD
alues greater than 0.2, and OR values greater than 2.25. Moving
ue north is the graphical equivalent of taking a derivative with
espect to R1 (positive change in R1, holding R0 constant). Simi-
larly, moving due south of the point falls below all three iso-
quants (negative change in R1 only). That intuition holds for any
pair of risks, including those below the 45-degree line or not on
the negative 45-degree line. For any fixed baseline risk R0, the
rankings of any two treatments will be the same for RR, RD,
and OR.
The situation changes when comparing points that do not
share the same baseline risk R0. To make our point simpler, we
have redrawn Figure 1 without the RD isoquants, to focus only
on RR and OR (see Fig. 2). We can compare any point to (0.4, 0.6)
and ask: Is one RR higher than the other? Do the RRs and ORs
have the same ranking? If the other point lies to the northwest
of (0.4, 0.6) in the area marked A, then it will have higher values
of both RR and OR. If it lies to the southeast (large area marked
D), then it will have lower values of both RR and OR. In these
cases, both RR and OR rank these points the same; there is no
rank reversal.
The interesting cases lie to the southwest and to the northeast
in the areas marked B and C. For example, take the point (0.6, 0.8)
in area C. This point has a lower RR than (0.4, 0.6) (RR 1.33 instead
of 1.5); as such, it lies below the RR isoquant. But it has a higher OR
than the point (0.4, 0.6) and lies above the OR isoquant. Therefore,
(0.6, 0.8) has a different ranking compared with (0.4, 0.6) when
using RR than when using OR.
We show two other examples, again focusing on just RR and
OR. Both examples lie along the sameOR isoquant, and so only the
RR is changing. One has a tiny area B and a relatively large area C
(see Fig. 3). The other is the opposite,with area B beingmuch larger
han area C (see Fig. 4). These examples show that location on the
graph affects the probability that other points in the vicinity will
have rank reversal problems. When both risks are small, the
chance that the OR of another point nearby exceeds the RR is
almost zero.
Finally, to bring RD back into the picture, we return to Figure
1, which has all three isoquants. In this figure, we see that there
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Fig 2 – Isoquants for the point (.4, .6). OR, odds ratio; RR,
risk ratio.are eight regions, not four. In two of them (A and H), there are no
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measure that disagrees with the other two measures about
which point has a higher numerical value. For example, points
in area E have a lower RR than (0.4, 0.6) but higher RD and OR.
When given the same data for an indirect comparison or meta-
analysis, researchers who report RR or OR could reach different
conclusions about which treatment is preferred, given that the
baseline risks are different. The areas B and F do not appear in
Figure 1.
In summary, after drawing a point R0,R1 on the graph and
the corresponding three isoquants, only the points entirely
above all three isoquants or entirely below all three have the
same ranking on all measures. While the area of the graph with
the same ranking is always in the majority, in our experience
reading the literature, studies that are compared with each
other often lie broadly along the southwest to the northeast
corridor, making the choice of measure (RR, RD, or OR) impor-
tant in the final comparison (e.g., [9]).
Uncertainty
Thus farwehave assumed that the risks are knownwith certainty,
as opposed to being estimated with error. In real clinical trials,
however, risks are estimated with uncertainty (with confidence
intervals or standard errors). This uncertainty does not change the
basic conclusions of this article, namely, that different risk mea-
sures can lead to different rank ordering. However, with uncer-
tainty, the comparisons of risk become probabilistic instead of
deterministic. That is, if one bootstrapped the rankings, taking
draws of each risk from the estimated distribution of risks, and
then computed the risk measures, the ranking may not always be
the same.
Software
We have written Stata software that illustrates rank reversal for
any baseline risk R0 and risk if treated R1. The program, called
graphiso, takes as input any risk pair R0, R1 and produces a
graph with isoquants for each of the three risk measures (RR,
RD, and OR). In addition, the program calculates the areas for
which each of the three risk measures generates a different
ranking. The areas can be interpreted as probabilities of rank
reversal only in the unlikely case of a uniform distribution of
risk. This program file and a help file are available from the
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Fig 3 – Isoquants for the point (.1, .2). OR, odds ratio; RR,
risk ratio.authors on request.As an example, our Stata program can recreate Figure 1 for
R0, R1 0.4, 0.6 and calculate areas with the command graphiso
.4 .6. The program displays the following table of areas:
RESULTS
Above RR, Above RD, Above OR 0.2933
Above RR, Above RD, Below OR 0.0000
Above RR, Below RD, Above OR 0.0239
Above RR, Below RD, Below OR 0.0161
Below RR, Above RD, Above OR 0.0267
Below RR, Above RD, Below OR 0.0000
Below RR, Below RD, Above OR 0.0239
Below RR, Below RD, Below OR 0.6161
Total area  1
All same 0.9095
OR different 0.0239
RR different 0.0428
RD different 0.0239
In this example, the two areas where all three measures agree on
the ranking (areas A and H) together comprise 90% of the area of
the unit square (see Fig. 1). Measuring risk by using an OR gener-
ates a ranking different from the other two measures in region G,
whichhas an area of 0.0239. However, areas B and F donot exist for
this risk pair—it is impossible for another point to have a lower OR
than (0.4, 0.6) while simultaneously having a higher RR and RD.
Best Practice Recommendations
Our results lead to several recommendations for best practice
when making indirect comparisons. First, given the conceptual
framework and study design, decide which measure is most ap-
propriate for the research. There is an extensive literature on the
differences between RR, RD, and OR (for guidance, see textbooks
by authors of [7,10–12] and articles [13–15]). For some study de-
signs, such as case-control studies, only the OR is possible. Atten-
tion should also be paid to clarity of presentation of results [16–22].
s a default, we recommend using one of the risk measures in-
tead of the OR, unless there is a conceptual justification favoring
he OR. Second, for studies that have a study design that allows
ppropriate reporting of either RRs or ORs [23], show whether the
ifferent measures would lead to the same or different rankings.
ither the result is robust across measures or the authors should
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Fig 4 – Isoquants for the point (.8, .9). OR, odds ratio; RR,
risk ratio.
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1140 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 1 3 7 – 1 1 4 0acknowledge that other measures would lead to different conclu-
sions and discuss this finding in light of the conceptual model.
Conclusions
The federal government is currently advocating head-to-head
clinical trials, with several drugs being tested at once against the
same placebo. This design both avoids the problem of comparing
treatments with different placebos and also will increase dramat-
ically the number of indirect comparisons being conducted in clin-
ical research.While themethods of Bucher et al. [1] will inform the
nalysis of these trials, the results of this study demonstrate the
mportance of the choice of risk measure when conducting indi-
ect comparisons. This study has several important conclusions.
irst, we have two main mathematical results. The first is that if
omparisons aremadewithin the same study to the same control,
hen the three measures will always have the same ranking. The
ore interesting result is that the choice of the risk measure mat-
ers whenmaking indirect comparisons of treatments with differ-
nt baseline risks. This result holds regardless of whether or not
here is uncertainty about the risks.
Our results have strong policy implications. Because research-
rs often choose a riskmeasure out of convenience or habit, policy
ecisions based on treatment ranking may be driven in part by
hese arbitrary decisions. Researchers need to confront the prob-
em by showing whether the results are sensitive to the choice of
isk measure and explain which measure is preferred for their
tudy andwhy. This supports the importance of the explicit state-
ent of a conceptual model and reference to that model in sup-
orting the choice of measures.
This brings us to our third main conclusion: nonlinear func-
ions are challenging to understand. The prior debate in the liter-
ture between RRs and ORs has often focused on themagnitude of
he effect [18,20,22]. The linear RDoffers complementary and valu-
ble information. RRs and ORs do not differ in their sign (direc-
ion), only in their numerical magnitude and therefore in their
nterpretation. Here we show a new problem. When making indi-
ect comparisons, RRs and ORs can lead to opposite conclusions
egarding which option to favor. Nonlinear functions, such as RRs
nd ORs, emphasize different aspects of risk and have different
roperties; these differences are consequential.
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